Novo Holdings A/S
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 20, 2024), Novo Holdings A/S reported 38 stock positions worth $1.9 billion. Its top holding was VG Morningstar TS MKT ETF-US (VTI) at 15.0% of the portfolio, followed by Brookfield (BN, 8.7%) and Tempus AI Class A (TEM, 7.7%). Compared with Q1 2024, it opened 6 new positions, sold out of 3, added to 10 and reduced 6. The biggest buy was a new position in VG Morningstar TS MKT ETF-US (VTI) and the biggest sale an exit from Edgewell Personal Care (EPC).
- Most Recent 13F
- Q2 2026
- Location
- HELLERUP, G7
- CIK
- 0001388325
- Portfolio Value
- $1.9B (Q2 2024)
- SEC Filing
- 0000950123-24-008900 ↗ filed Aug 20, 2024
Holdings Value
Holdings 38 stocks · $1.9B
| VTI VG Morningstar TS MKT ETF-US | 14.98% | 1,038,550 | $277.8M | New |
| BN Brookfield Corp. | 8.69% | 3,880,230 | $161.2M | No change |
| TEM Tempus AI Inc. Class A | 7.69% | 4,074,419 | $142.6M | New |
| ASML ASML Holding NV-NY Reg SHS | 7.35% | 133,336 | $136.4M | Reduce -26.9% |
| CRM Salesforce Inc. | 6.66% | 480,160 | $123.4M | No change |
| EWTX Edgewise Therapeutics Inc. | 6.16% | 6,344,430 | $114.3M | New |
| CORT Corcept Therapeutics Inc. | 4.22% | 2,411,362 | $78.3M | No change |
| PCVX Vaxcyte Inc. | 3.87% | 950,000 | $71.7M | Add +12.4% |
| INSM Insmed Inc. | 2.89% | 800,000 | $53.6M | Reduce -40.3% |
| MIRM Mirum Pharmaceuticals Inc. | 2.76% | 1,500,000 | $51.3M | No change |
| CRNX Crinetics Pharmaceuticals Inc. | 2.41% | 1,000,000 | $44.8M | Reduce -9.0% |
| CABO Cable One Inc. | 2.26% | 118,403 | $41.9M | No change |
| BMRN Biomarin Pharmaceutical Inc. | 2.17% | 490,000 | $40.3M | Add +8.9% |
| MRUS Merus NV | 2.15% | 675,000 | $39.9M | New |
| AAPL Apple Inc. | 2.08% | 182,960 | $38.5M | No change |
| BABA Alibaba Group Holding-SP ADR | 1.94% | 500,827 | $36.1M | No change |
| PHVS Pharvaris NV | 1.75% | 1,725,000 | $32.4M | Add +47.7% |
| CLDX Celldex Therapeutics Inc. | 1.70% | 850,000 | $31.5M | New |
| FDMT 4D Molecular Therapeutics Inc. | 1.58% | 1,400,000 | $29.4M | No change |
| LANZATECH GLOBAL INC | 1.58% | 15,814,845 | $29.3M | No change |
| ALNY Alnylam Pharmaceuticals Inc. | 1.55% | 118,383 | $28.8M | No change |
| AVBP Arrivent Biopharma Inc. | 1.50% | 1,500,000 | $27.8M | Add +39.3% |
| VRDN Viridian Therapeutics Inc. | 1.40% | 2,000,000 | $26.0M | Add +81.8% |
| CRGX Cargo Therapeutics Inc. | 1.37% | 1,544,000 | $25.4M | Add +23.5% |
| FOLD Amicus Therapeutics Inc. | 1.34% | 2,500,000 | $24.8M | No change |
| BAM Brookfield Asset Mgmt-A | 1.29% | 627,207 | $23.9M | No change |
| RCKT Rocket Pharmaceuticals Inc. | 1.28% | 1,100,000 | $23.7M | Add +4.8% |
| LXEO Lexeo Therapeutics Inc. | 1.25% | 1,450,500 | $23.3M | Reduce -11.5% |
| BPMC Blueprint Medicines Corp. | 1.02% | 175,000 | $18.9M | Reduce -51.2% |
| KYTX Kyverna Therapeutics Inc. | 0.71% | 1,750,000 | $13.1M | Add +150.0% |
| MORF Morphic Holding Inc. | 0.69% | 375,000 | $12.8M | New |
| VERV Verve Therapeutics Inc. | 0.63% | 2,400,000 | $11.7M | Add +20.0% |
| MGX Metagenomi Therapeutics Inc. | 0.40% | 1,800,000 | $7.3M | Add +3.5% |
| IOBTQ Io Biotech Inc. | 0.28% | 4,429,449 | $5.2M | Reduce -12.9% |
| ABCL Abcellera Biologics Inc. | 0.18% | 1,126,915 | $3.3M | No change |
| MQ Marqeta Inc. | 0.13% | 441,558 | $2.4M | No change |
| GALECTO INC | 0.06% | 2,497,791 | $1.2M | No change |
| SPRO Spero Therapeutics Inc. | 0.03% | 468,902 | $610K | No change |
Portfolio Sells Q1 2024 → Q2 2024
| EPC Edgewell Personal Care Co. | Sold out | 0.00% | −7.98 |
| ASML ASML Holding NV-NY Reg SHS | Reduce -26.9% | 7.35% | −4.87 |
| BPMC Blueprint Medicines Corp. | Reduce -51.2% | 1.02% | −1.33 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -9.0% | 2.41% | −1.13 |
| INSP Inspire Medical Systems Inc. | Sold out | 0.00% | −0.97 |
| LXEO Lexeo Therapeutics Inc. | Reduce -11.5% | 1.25% | −0.52 |
| IOBTQ Io Biotech Inc. | Reduce -12.9% | 0.28% | −0.33 |
| TMCI Treace Medical Concepts Inc. | Sold out | 0.00% | −0.32 |
| INSM Insmed Inc. | Reduce -40.3% | 2.89% | +0.38 |
Portfolio Buys Q1 2024 → Q2 2024
| VTI VG Morningstar TS MKT ETF-US | New | 14.98% | +14.98 |
| TEM Tempus AI Inc. Class A | New | 7.69% | +7.69 |
| EWTX Edgewise Therapeutics Inc. | New | 6.16% | +6.16 |
| MRUS Merus NV | New | 2.15% | +2.15 |
| CLDX Celldex Therapeutics Inc. | New | 1.70% | +1.70 |
| MORF Morphic Holding Inc. | New | 0.69% | +0.69 |
| AVBP Arrivent Biopharma Inc. | Add +39.3% | 1.50% | +0.17 |
| VRDN Viridian Therapeutics Inc. | Add +81.8% | 1.40% | +0.07 |
| PHVS Pharvaris NV | Add +47.7% | 1.75% | −0.11 |
| PCVX Vaxcyte Inc. | Add +12.4% | 3.87% | −0.11 |
| KYTX Kyverna Therapeutics Inc. | Add +150.0% | 0.71% | −0.49 |
| BMRN Biomarin Pharmaceutical Inc. | Add +8.9% | 2.17% | −0.54 |
| CRGX Cargo Therapeutics Inc. | Add +23.5% | 1.37% | −0.56 |
| RCKT Rocket Pharmaceuticals Inc. | Add +4.8% | 1.28% | −0.67 |
| MGX Metagenomi Therapeutics Inc. | Add +3.5% | 0.40% | −0.87 |
| VERV Verve Therapeutics Inc. | Add +20.0% | 0.63% | −1.20 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 25 | $1.7B | EWTX, ASML, COAG, BN, MPLT |
| Q1 2026 | 22 | $1.2B | EWTX, BN, ASML, MIRM, MPLT |
| Q4 2025 | 24 | $1.3B | BN, EWTX, ASML, MIRM, CRM |
| Q3 2025 | 27 | $1.6B | VTI, BN, ASML, MIRM, EWTX |
| Q2 2025 | 29 | $1.4B | VTI, BN, ASML, CRM, MIRM |
| Q1 2025 | 31 | $1.3B | VTI, BN, EWTX, ASML, CRM |
| Q4 2024 | 34 | $1.7B | VTI, BN, TEM, EWTX, ASML |
| Q3 2024 | 37 | $2.0B | VTI, TEM, BN, EWTX, CORT |
| Q2 2024Amended | 38 | $1.9B | VTI, BN, TEM, ASML, CRM |
| Q1 2024 | 35 | $1.4B | ASML, BN, CRM, EPC, CORT |